Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Rifampicin +/- Levofloxacin for Pediatric TBM
NCT02958709Phase 2Completed
- Sponsor
- Johns Hopkins University
- Start
- Feb 2017
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of rifampicin and levofloxacin in tuberculous meningitis (TBM) (3 arms), sponsored by Johns Hopkins University. Primary endpoints: Volume of Distribution of Rifampicin, Oral Clearance of Rifampicin and 8 more. Started Feb 2017; status: completed.
02
Drugs
rifampicinlevofloxacin
03
Conditions
tuberculous meningitis (TBM)
Beyond the preview
Go deeper on NCT02958709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02958709.